The rising prevalence levels of cardiovascular diseases, aneurysms among other vascular disorders have fueled demand for these products. In addition to encouraging patients to seek alternative methods which are non-invasive compared to traditional surgeries; transcatheter embolization has become popular in the field of vascular intervention.
Technological advancements define the dynamics shaping the transcatheter embolization and occlusion devices market today. They have contributed greatly towards enhancing safety, effectiveness as well as accuracy in vascular interventions through device design innovations i.e., biomaterials used as delivery systems among others. As a result there is growth within these therapeutic options hence more treatment alternatives available for interventional radiologists due to bioresorbable embolic agents being made plus developmental catheters manufactured specifically for this purpose have been refined over time. T
The market dynamics are further influenced by the increasing preference for outpatient and ambulatory procedures. Less invasive interventions in line with patients’ desires for shorter recuperation periods, less hospitalizations and reduced procedural risks have made transcatheter embolization and occlusion devices popular among people. Consequently, these advantages make them pertinent to the market due to the fact that most of them are done on an outpatient basis which results in an increase in this trend. In addition, there is potential for saving costs linked to outpatient treatments especially within healthcare systems which aim at achieving more efficiency.
However challenges within the market dynamics include involvement of complications associated with some procedures complexity and learning curve when using new technologies. Despite being minimally invasive solutions provided by transcatheter embolization and occlusion devices; certain complicated procedures may necessitate special trainings as well as experience. Therefore, continuous education about these products poses a challenge towards their adoption by many health care providers.
Regulatory considerations have significant impacts on the market dynamics of transcatheter embolization & occlusion devices manufacturers. As such, stringent regulatory conditions on product approval as well as entry into the markets dictate developmental timelines and strategies used by manufacturers alike. Thus, fulfilling regulatory standards including safety together with efficacy evaluation becomes important if patient welfare is to be ensured along with successful marketing campaign for these products.
Transcatheter embolization and occlusion devices market dynamics vary geographically due to regional healthcare needs, disease prevalence, and economic factors. Developed regions with advanced healthcare infrastructures and higher burden of cardiovascular diseases tend to have these devices at a high adoption rate. However, increased adoption is being witnessed within emerging economies fueled by increasing cases of vascular disorders as well as expansion of interventional radiology capacities.
The Transcatheter Embolization and Occlusion Devices Market is expected to reach USD 10.8 billion by 2032 at 10.1% CAGR during the forecast period 2023-2032.
March 2023: The Society for Cardiovascular Angiography and Interventions (SCAI) and the Heart Rhythm Society (HRS) have produced a revised expert consensus statement to provide standardized methods for transcatheter left atrial appendage closure (LAAC). The SCAI and HRS both emphasized the importance of creating an updated consensus statement that offers guidelines rooted on current, evidence-based best practices for the implantation of transcatheter LAA occlusion (LAAO) devices. The text was enriched with new information from further clinical trial data and user experience with recently announced technology. Left atrial appendage closure is a surgery that is performed with little invasion in order to decrease the likelihood of stroke that is linked to atrial fibrillation (AFib). The presence of arrhythmia is linked to a four- to five-fold higher likelihood of experiencing an ischemic stroke. Additionally, arrhythmia is responsible for a quarter of the 700,000 cases of cerebrovascular accidents that happen in the United States every year.
The market of transcatheter embolization and occlusion devices is influenced by the growing number of tumor surgeries and the efficacy of these devices that efficiently avoids complications. Potential surgeons are shifting their surgical patterns toward transcatheter embolization and occlusion devices because of the benefits and variety. For instance, the non-coil segments such as flow diverting devices, and embolization accessories are efficient in carrying out the surgeries and they are commercially available as well. they are considered minimally invasive surgeries that let the patients go to their homes soon after the surgeries. Therefore this reduces the cost of staying at the hospital and other costs.
The transcatheter embolization and occlusion devices market growth is influenced by varied applications such as peripheral vascular diseases, oncology, neurology, and fatal neurological disorders. Moreover, a recent report from the neuro-interventional surgery stated that there are over 140 Guglielmi coils available in the market in varied sizes for various applications, and over 1,25,000 patients were treated using them. such reports are augmenting the overall growth of The transcatheter embolization and occlusion devices industry.
The increasing prevalence of tumor procedures and the efficiency of these devices in preventing complications have a direct impact on the transcatheter embolization and occlusion devices market. Transcatheter embolization and occlusion devices are gaining popularity with potential surgeons due to their many uses and minimal risk of complications. Non-coil sections, including flow diverting devices and embolization accessories, are effective in performing the procedures and may be purchased in stores. These procedures are considered minimally invasive since they require minor incisions and allow patients to recover at home. Consequently, this results in savings on healthcare bills and other expenses.
Transcatheter embolization devices, together with imaging technology, can reduce or eliminate the need for invasive surgery. This means the patient avoids surgical intervention for minor conditions. Because of this, patients receive better care than ever before. Market growth for transcatheter embolization and occlusion devices is anticipated mostly from these sources.
There are promising prospects for the development of the transcatheter embolization and occlusion devices market as a whole due to the availability of a variety of devices based on applications that are effective in reducing the rate of surgeries and lead to minimally invasive surgeries as well as other benefits.
Favorable circumstances for the expansion of the transcatheter embolization and occlusion devices business throughout the forecast period are presented by the introduction of new laws and regulations by the government and the FDA organization that aid in the improvement of the medical facilities. In addition, occlusion techniques are regarded as effective by surgeons for the treatment of liver, kidney, breast, and pancreatic cancers. Opportunities for the transcatheter embolization and occlusion devices market to expand throughout the projected period are promising due to the rising incidence of cancer and advances in oncology therapy.
December 2022: Abbott will begin offering the Navitor Transcatheter Aortic Valve implantation (TAVI) system in India to treat patients with severe aortic stenosis who are at high or extreme risk for surgery. Through advancements like the design of the Navitor valve, the business is pushing TAVI (also known as TAVR, or transcatheter aortic valve replacement) treatments forward. TAVI is an alternative to surgical aortic valve replacement that can help alleviate symptoms and prolong the lives of those suffering from this illness.
During the COVID 19, the industrial operations were reduced and the medical supplies were not produced to meet the increasing demand. However, with higher regulations, the industries were producing the medical supplies and the medical catheters that are required for the medical treatments. The demand for respiratory support devices, and life-supporting machines was increasing during the pandemic, as the COVID cases were rapidly increasing.
The leading manufacturers of this personal protective equipment were focusing on capitalization of the products and commercialization to ensure the supply meets the rising demand. Therefore the overall growth of the transcatheter embolization and occlusion devices industry was unaffected due to pandemics.
Market drivers:
The transcatheter devices are considered safer instruments as they are less invasive and efficient in carrying out the surgeries. They effectively avoid complications and therefore the surgeons are shifting toward the non-coil devices and catheters in recent times.
The utilization of transcatheter embolization devices with the usage of radiology eliminates the surgeries and thereby decreases morbidity or mortality rate. Therefore the patient is also not gone under the knife for smaller ailments. Therefore enhanced medical treatment is provided with the help of this equipment. Such factors are considered the major drivers of the transcatheter embolization and occlusion devices industry.
Market opportunities:
The presence of a wide range of devices based on the applications that are effective in reducing the rate of surgeries and lead to minimally invasive surgeries and other benefits are presenting lucrative opportunities for the overall growth of the transcatheter embolization and occlusion devices industry.
The advent of new policies and regulations by the government and FDA organization that helps in the betterment of the medical facilities are presenting favorable conditions for the growth of the transcatheter embolization and occlusion devices industry during the forecast period. Moreover, surgeons consider the occlusion techniques efficient in treating cancer in the liver, kidneys, breasts, and pancreatic. The increasing prevalence of cancer and development in oncology treatment is presenting lucrative opportunities for the overall growth of the transcatheter embolization and occlusion devices industry during the forecast period.
Market restraints:
The cost involved in the development and maintenance of this equipment and the stringent regulations involved in the manufacturing and operation of this equipment are considered the key restraints of the transcatheter embolization and occlusion devices industry.
The significant morbidity rate of about 58% in the selective embolization method, other issues such as leakage of bile fluid, liver abscesses, and other factors are considered the major restraints of the transcatheter embolization and occlusion devices industry.
Market challenges:
Lack of skilled professionals that can handle these processes efficiently and the error rate during the surgeries are considered the major challenge for the overall growth of the transcatheter embolization and occlusion devices industry.
The occurrence of lesions and increased morbidity rate and other complications such as side effects, generation of tumors after the surgeries are increasing. Such factors are considered the major challenge for the overall growth of the transcatheter embolization and occlusion devices industry.
The growth of the transcatheter embolization and occlusion devices industry is influenced by the efficient treatment offered while removing the blockage of the blood vessels or while treating the abnormal vascular vessels. The treatment is considered effective as it involves placing the embolic agents or synthetic materials onto the blood vessels and thereby blocking the blood flow, such factors will reduce the loss of blood during the surgeries and thereby reduce the rate of mortality.
The increasing number of chronic illnesses and coronary heart diseases across the globe, obesity conditions, and other risk factors are propelling the growth of the transcatheter embolization and occlusion devices industry. the presence of reimbursement policies related to medical procedures and increased adoption of advanced treatment across the globe are propelling the overall growth of the transcatheter embolization and occlusion devices industry.
The key benefits of the transcatheter embolization and occlusion devices such as enhanced efficiency, and the presence of varied products such as flow diverters, accessories, liquid embolic, embolization coils, and significant others that perform the specific tasks efficiently are considered as the major drivers of transcatheter embolization and occlusion devices industry. the advent of new equipment in the industry by the leading market players is also propelling the overall growth of the transcatheter embolization and occlusion devices industry.
For instance, in the year 2021, one of the leading market players, Jasper has introduced detachable coils that have gotten approval from the NMPA and are available for commercialization. This equipment was considered efficient in the medical industry, Moreover, the reimbursement policies are flowing in due to the favorable economic conditions and better healthcare infrastructure.
Based on type:
Based on Application:
Currently, the Asia-pacific region is expected to grow at a higher rate due to the potential initiatives from the government and developing medical infrastructure across the region. China was spending over USD 590.62 billion in the year 2015 and the expenditure has been rapidly increasing in recent times. The medical tourism industry and other advanced technologies in the medical sector have stimulated the overall growth of the Transcatheter Embolization and Occlusion Devices industry.
On the other hand, North America is projecting higher market growth due to the presence of established market players, experienced health care professionals, and well-defined regulations. The rapid growth in the economic condition is expected to stimulate the growth of the transcatheter embolization and occlusion devices industry.
One of the leading market players, BTC plc had joined hands with Roxwood medical which is known for its excellent portfolio of advanced cardiovascular catheters. They have manufactured efficient catheters that have helped in the surgeries related to cardiovascular diseases and peripheral artery disease.
One of the leading market players, Boston had joined with apama medical Inc, which is a private organization that is known for its radiofrequency single-shot balloon catheter system that is efficient for the patients at the stage of atrial fibrillation. This atrial fibrillation is a condition in which the heart shivers and the condition might be fatal.
This report has covered:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)